Michael Kors Holdings Limited (NYSE:KORS) and Luxottica Group (MTA:LUX) (NYSE:LUX) has announced that they have signed a new and exclusive eyewear license agreement for the Michael Kors Collection and MICHAEL Michael Kors eyewear. The first collection produced with Luxottica will launch in January 2015. Michael Kors Holdings Ltd (NYSE:KORS) shares after opening at $91.54 moved to $93.97 on last trade day and at the end of the day closed at $93.20. Company price to sales ratio in past twelve months was calculated as 6.36 and price to cash ratio as 22.95. Michael Kors Holdings Ltd (NYSE:KORS) showed a positive weekly performance of 6.98%.
Revance Therapeutics Inc. (NASDAQ:RVNC) reported positive results from its phase 1/2 study involving RT002 as a treatment for the reduction of frown lines. According to the results from its study, 94% of the 48 patients with moderate to severe frown lines prior to treatment had either “none” or “mild” frown lines at maximum frown four weeks after treatment. Revance Therapeutics Inc. (NASDAQ:RVNC) shares advanced 25.75% in last trading session and ended the day on $35.99.
US gaming and lottery software supplier Scientific Games Corporation(NASDAQ:SGMS) has extended its relationship with La Française des Jeux (FDJ) through a deal to supply the French operator with instant lottery games for a further three years. Scientific Games Corp (NASDAQ:SGMS) shares moved up 8.26% in last trading session and was closed at $12.32, while trading in range of $12.01 – $12.75. Scientific Games Corp (NASDAQ:SGMS) year to date (YTD) performance is -27.23%.
ImmunoCellular Therapeutics, Ltd. (NYSE MKT: IMUC) announced that the abstract describing the Company’s phase II trial of dendritic cell-based cancer vaccine ICT-107 in newly diagnosed glioblastoma has been accepted for an oral presentation at the 2014 American Society for Clinical Oncology annual meeting, to be held in Chicago May 30-June 3, 2014. ImmunoCellular Therapeutics Ltd (NYSEMKT:IMUC) weekly performance is 4.17%. On last trading day company shares ended up $1.25. ImmunoCellular Therapeutics Ltd (NYSEMKT:IMUC) distance from 50-day simple moving average (SMA50) is -2.04%. Analysts mean target price for the company is $5.69.
Leave a Reply